Compare ZKIN & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZKIN | PSTV |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.5M | 27.9M |
| IPO Year | 2017 | 2016 |
| Metric | ZKIN | PSTV |
|---|---|---|
| Price | $1.48 | $6.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $55.00 |
| AVG Volume (30 Days) | 9.3K | ★ 3.5M |
| Earning Date | 09-29-2025 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,213,000.00 |
| Revenue This Year | N/A | $21.93 |
| Revenue Next Year | N/A | $279.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.93 | $0.13 |
| 52 Week High | $4.47 | $6.05 |
| Indicator | ZKIN | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 43.28 | 91.27 |
| Support Level | $1.26 | $0.37 |
| Resistance Level | $2.09 | N/A |
| Average True Range (ATR) | 0.19 | 0.59 |
| MACD | -0.02 | 0.42 |
| Stochastic Oscillator | 22.55 | 99.37 |
ZK International Group Co Ltd is engaged in the manufacture and marketing of metal pipes. The company is specialized in producing double-press thin-walled stainless steel tubes and fittings, carbon steel tubes and fittings, single-press tubes and fittings, and stainless-steel strips. The products are used in restaurants, hotels, hospitals, firefighting, food, beverage, ships, engines, industrial seawater desalination and systems of direct-drinking water, cold /hot water supply, city water supply, and gas of large/middle scale construction projects.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).